Stock Analysis on Net

Cytokinetics Inc. (NASDAQ:CYTK)

$22.49

This company has been moved to the archive! The financial data has not been updated since November 3, 2023.

Economic Value Added (EVA)

Microsoft Excel

Paying user area

The data is hidden behind: . Unhide it.

This is a one-time payment. There is no automatic renewal.


We accept:

Visa Mastercard American Express Maestro Discover JCB PayPal Google Pay
Visa Secure Mastercard Identity Check American Express SafeKey

Economic Profit

Cytokinetics Inc., economic profit calculation

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Net operating profit after taxes (NOPAT)1
Cost of capital2
Invested capital3
 
Economic profit4

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 NOPAT. See details »

2 Cost of capital. See details »

3 Invested capital. See details »

4 2022 Calculation
Economic profit = NOPAT – Cost of capital × Invested capital
= × =


The financial data indicates significant challenges in profitability and economic value generation across the reviewed periods.

Net operating profit after taxes (NOPAT)
The NOPAT figures exhibit a predominantly negative trend throughout the years. Starting at -105,906 thousand USD in 2018, the loss widened to -119,531 thousand USD in 2019, improved substantially to -31,573 thousand USD in 2020, then deteriorated sharply to -193,076 thousand USD in 2021 and further deepened to -460,021 thousand USD in 2022. The temporary improvement in 2020 appears as an anomaly within an overall deteriorating pattern, suggesting inconsistent operational performance and possibly external or one-off factors in that year.
Cost of Capital
The cost of capital percentage shows minor fluctuations, starting at 13.28% in 2018, slightly decreasing to 13.2% in 2019 and 12.4% in 2020, increasing again to 13.1% in 2021, and then reducing to 12.45% in 2022. These modest variances suggest relatively stable capital costs with some minor sensitivity to market or company-specific risk factors.
Invested Capital
Invested capital values reveal considerable volatility. The investment base was negative in the years 2018, 2019, and 2020, with amounts of -78,273, -106,877, and -87,987 thousand USD, respectively. In 2021, the invested capital turned positive to 91,721 thousand USD, before reverting to a negative position of -117,411 thousand USD in 2022. This erratic pattern may reflect significant adjustments or accounting impacts related to asset bases, liabilities, or capital structure changes, indicating instability in capital deployment or reporting.
Economic Profit
Economic profit remained negative throughout all periods, closely mirroring the trends observed in NOPAT. It started at -95,515 thousand USD in 2018, deepened to -105,428 thousand USD in 2019, showed improvement to -20,667 thousand USD in 2020, then significantly worsened to -205,095 thousand USD in 2021, and reached its lowest point of -445,403 thousand USD in 2022. The consistent negative economic profit indicates the company has not generated returns above its cost of capital in any year, highlighting sustained value destruction.

Overall, the data suggest that the company faced enduring challenges in generating positive operating returns and economic profits. The considerable fluctuations in invested capital and the persistent negative profitability metrics underscore operational and financial instability. The stable cost of capital indicates that external financing conditions were relatively constant, placing emphasis on internal factors for performance issues. Immediate attention to operational efficiencies and capital management appears warranted to reverse negative trends.


Net Operating Profit after Taxes (NOPAT)

Cytokinetics Inc., NOPAT calculation

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Net loss
Deferred income tax expense (benefit)1
Increase (decrease) in deferred revenue2
Increase (decrease) in equity equivalents3
Interest expense
Interest expense, operating lease liability4
Adjusted interest expense
Tax benefit of interest expense5
Adjusted interest expense, after taxes6
Interest income
Investment income, before taxes
Tax expense (benefit) of investment income7
Investment income, after taxes8
Net operating profit after taxes (NOPAT)

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 Elimination of deferred tax expense. See details »

2 Addition of increase (decrease) in deferred revenue.

3 Addition of increase (decrease) in equity equivalents to net loss.

4 2022 Calculation
Interest expense on capitalized operating leases = Operating lease liability × Discount rate
= × =

5 2022 Calculation
Tax benefit of interest expense = Adjusted interest expense × Statutory income tax rate
= × 21.00% =

6 Addition of after taxes interest expense to net loss.

7 2022 Calculation
Tax expense (benefit) of investment income = Investment income, before tax × Statutory income tax rate
= × 21.00% =

8 Elimination of after taxes investment income.


Net Loss Trend
The net loss demonstrates a consistent and significant increase over the five-year period. Beginning at approximately -106.3 million US dollars at the end of 2018, the net loss gradually worsened to -121.7 million in 2019 and further to -127.3 million in 2020. A sharper escalation is observed in 2021, with the net loss reaching approximately -215.3 million US dollars, followed by a substantial further decline to -389.0 million US dollars in 2022. This indicates increasing expenses, reduced revenues, or other factors contributing to growing financial challenges over time.
Net Operating Profit After Taxes (NOPAT) Trend
NOPAT follows a somewhat different trajectory from net loss but remains negative throughout the observed period. It starts at around -105.9 million US dollars in 2018 and deteriorates slightly to -119.5 million in 2019. In 2020, there is a notable improvement, with NOPAT improving substantially to approximately -31.6 million US dollars, indicating either a reduction in operating losses or improved operational efficiency during that year. However, this improvement is not sustained, as NOPAT declines sharply in 2021 to around -193.1 million, and further worsens to an estimated -460.0 million US dollars by the end of 2022. This sharp downturn in recent years suggests significant operational challenges impacting profitability after taxes.
Overall Financial Performance Insights
The increasing net losses alongside the fluctuating but largely negative NOPAT values suggest persistent financial difficulties with a notable deterioration in both net loss and operating profitability in the last two years of the data. The brief improvement in NOPAT in 2020 could reflect transient operational efficiencies or cost management, which were not maintained amid subsequent increases in losses. This pattern may warrant a deeper investigation into the underlying causes such as increased expenses, investments, or operational disruptions in the 2021 and 2022 periods.

Cash Operating Taxes

Cytokinetics Inc., cash operating taxes calculation

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Income tax provision
Less: Deferred income tax expense (benefit)
Add: Tax savings from interest expense
Less: Tax imposed on investment income
Cash operating taxes

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).


The data presents a clear upward trend in cash operating taxes for the company over the observed period from December 31, 2018, to December 31, 2022. Starting at 102 thousand US dollars in 2018, the cash operating taxes increased significantly each year, peaking at 5,911 thousand US dollars by the end of 2021. However, in 2022, there was a noticeable decline to 4,236 thousand US dollars, indicating a reduction of approximately 28% from the previous year.

The absence of values for the income tax provision across all periods indicates either that such data was not reported or that there were no income tax provisions recognized during these years.

Overall, the cash operating taxes show a consistent upward trajectory with the exception of the last year, where a decline suggests possible changes in tax policy, operational conditions, or other factors impacting the tax liability related to cash operations. The lack of income tax provision data limits the ability to analyze comprehensive tax expense trends.


Invested Capital

Cytokinetics Inc., invested capital calculation (financing approach)

US$ in thousands

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Current portion of term loan
Short-term finance lease liabilities
Term loan, net, excluding current portion
Convertible notes, net
Long-term finance lease liabilities
Operating lease liability1
Total reported debt & leases
Stockholders’ equity (deficit)
Net deferred tax (assets) liabilities2
Deferred revenue3
Equity equivalents4
Accumulated other comprehensive (income) loss, net of tax5
Adjusted stockholders’ equity (deficit)
Construction in progress6
Available-for-sale investments7
Invested capital

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 Addition of capitalized operating leases.

2 Elimination of deferred taxes from assets and liabilities. See details »

3 Addition of deferred revenue.

4 Addition of equity equivalents to stockholders’ equity (deficit).

5 Removal of accumulated other comprehensive income.

6 Subtraction of construction in progress.

7 Subtraction of available-for-sale investments.


Total reported debt & leases
The total reported debt and leases show a consistent and significant upward trend over the five-year period. Beginning at $52.8 million in 2018, the figure rose sharply to $136.1 million in 2019 and remained relatively stable in 2020. From 2020 onwards, the debt level surged substantially, reaching $271.2 million in 2021 and further increasing to $751.3 million by the end of 2022. This dramatic rise in debt indicates a growing reliance on external financing or obligations over time.
Stockholders’ equity (deficit)
Stockholders’ equity exhibits considerable volatility throughout the period. Initially, it was positive at $25.9 million in 2018. However, it turned negative in 2019, reflecting a deficit of approximately $10.9 million. The position improved markedly in 2020 and 2021, reaching a peak value of $243.9 million in 2021, indicating a strong equity base during these years. Nevertheless, by the end of 2022, stockholders’ equity declined sharply into a deficit of $107.9 million, suggesting a deterioration in the company’s net asset position in the most recent year.
Invested capital
Invested capital remained negative for the majority of the analyzed period, starting at a deficit of $78.3 million in 2018 and worsening slightly to $106.9 million in 2019. There was a modest improvement in 2020, yet the figure remained negative. A notable positive shift occurred in 2021, with invested capital rising to a positive $91.7 million, implying effective investment and capital utilization during that year. This positive trend was reversed in 2022, with invested capital declining sharply back into negative territory at $117.4 million, reflecting a significant decrease in net capital invested in the company.

Cost of Capital

Cytokinetics Inc., cost of capital calculations

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2022-12-31).

1 US$ in thousands

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2021-12-31).

1 US$ in thousands

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2020-12-31).

1 US$ in thousands

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2019-12-31).

1 US$ in thousands

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »

Capital (fair value)1 Weights Cost of capital
Equity2 ÷ = × =
Debt3 ÷ = × × (1 – 21.00%) =
Operating lease liability4 ÷ = × × (1 – 21.00%) =
Total:

Based on: 10-K (reporting date: 2018-12-31).

1 US$ in thousands

2 Equity. See details »

3 Debt. See details »

4 Operating lease liability. See details »


Economic Spread Ratio

Cytokinetics Inc., economic spread ratio calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Selected Financial Data (US$ in thousands)
Economic profit1
Invested capital2
Performance Ratio
Economic spread ratio3
Benchmarks
Economic Spread Ratio, Competitors4
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 Economic profit. See details »

2 Invested capital. See details »

3 2022 Calculation
Economic spread ratio = 100 × Economic profit ÷ Invested capital
= 100 × ÷ =

4 Click competitor name to see calculations.


The financial data reveals several notable trends over the five-year period ending December 31, 2022. The economic profit figures demonstrate significant fluctuations with a general pattern of negative values throughout the period under review. Specifically, economic profit worsened in 2019 compared to 2018, improving somewhat in 2020 but then markedly deteriorating in subsequent years, reaching the lowest point in 2022.

Invested capital shows considerable volatility as well. Initial values in 2018 and 2019 are negative and increase in magnitude, followed by a sizable positive shift in 2021. However, in 2022, invested capital reverses sharply back to a negative figure. This pattern indicates instability or perhaps changes in capital structure or asset valuation over the studied periods.

The economic spread ratio data is largely unavailable, with only one data point recorded for 2021, which indicates a negative spread of -223.61%. This suggests that the returns on invested capital were significantly below the cost of capital during that year.

Economic Profit Trend
Economic profit remained negative each year, with the largest loss observed in 2022 at -445,403 thousand US dollars. The value improved from 2019 to 2020 but deteriorated sharply after that, reflecting growing economic losses.
Invested Capital Variability
Invested capital fluctuated significantly, with a negative capital base in most years except for a positive value in 2021. The negative invested capital in multiple years may reflect accounting practices, liabilities exceeding assets, or other underlying financial dynamics.
Economic Spread Ratio Insight
The sole available economic spread ratio in 2021, at -223.61%, indicates returns far below cost. The absence of data for other years makes it difficult to assess the consistency of this performance metric over time.
Overall Financial Implications
The data implies persistent financial challenges, characterized by sustained negative economic profits and volatile invested capital. The substantial negative economic spread observed in 2021 further highlights inefficiencies in generating returns from capital investment.

Economic Profit Margin

Cytokinetics Inc., economic profit margin calculation, comparison to benchmarks

Microsoft Excel
Dec 31, 2022 Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018
Selected Financial Data (US$ in thousands)
Economic profit1
 
Revenues
Add: Increase (decrease) in deferred revenue
Adjusted revenues
Performance Ratio
Economic profit margin2
Benchmarks
Economic Profit Margin, Competitors3
AbbVie Inc.
Amgen Inc.
Bristol-Myers Squibb Co.
Danaher Corp.
Eli Lilly & Co.
Gilead Sciences Inc.
Johnson & Johnson
Merck & Co. Inc.
Pfizer Inc.
Regeneron Pharmaceuticals Inc.
Thermo Fisher Scientific Inc.
Vertex Pharmaceuticals Inc.

Based on: 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31).

1 Economic profit. See details »

2 2022 Calculation
Economic profit margin = 100 × Economic profit ÷ Adjusted revenues
= 100 × ÷ =

3 Click competitor name to see calculations.


The financial data reveals significant fluctuations and generally adverse trends in the company's economic profit and adjusted revenues over the five-year period ending December 31, 2022.

Economic Profit
Economic profit figures demonstrate consistent negative values across all years, indicating persistent losses. After an initial negative value of approximately -95.5 million US dollars in 2018, the losses deepened to over -105 million in 2019. A notable improvement occurred in 2020, with losses narrowing significantly to around -20.7 million. However, this recovery was short-lived, as economic profit sharply declined again in 2021 to approximately -205.1 million US dollars and further worsened drastically in 2022, reaching a level of approximately -445.4 million US dollars. This volatility signifies substantial challenges in generating value beyond the cost of capital.
Adjusted Revenues
Adjusted revenues exhibited considerable variability within the period. Beginning at around 31.5 million US dollars in 2018, revenues declined slightly in 2019 to approximately 26.9 million. A pronounced surge was recorded in 2020, with revenues soaring to about 142.8 million US dollars, the peak in this timeframe. Subsequently, revenues decreased significantly in 2021 to approximately 70.4 million, and declined further to 7.6 million in 2022. The sharp decline after 2020 suggests difficulties in revenue retention or generation, which likely contributed to the deepening losses observed in economic profit.
Economic Profit Margin
The economic profit margin, expressed as a percentage, aligns with the trends seen in economic profit, with consistently negative margins throughout the years. In 2018 and 2019, the margins were severely negative at approximately -303.2% and -392.4%, respectively. A marked improvement occurred in 2020 with a margin near -14.5%, indicating a temporary approach toward break-even economic profitability. Nevertheless, this improvement was reversed thereafter, with the margin plummeting to -291.2% in 2021 and an extreme decline to nearly -5869.8% in 2022. This extreme negative margin in the final year underscores an intensification of losses relative to revenues and capital employed.

Overall, the data portrays a company struggling with persistent and increasingly severe economic losses despite a brief spike in revenues and a temporary narrowing of losses in 2020. The extreme negative economic profit margins in the later years point to significant operational or financial challenges requiring addressing. The steep decline in adjusted revenues from 2020 onward likely exacerbates the unfavorable profitability trend, suggesting issues with sustaining or growing core income streams.